Vinva Investment Management Ltd Raises Position in Johnson & Johnson (NYSE:JNJ)

Vinva Investment Management Ltd grew its position in Johnson & Johnson (NYSE:JNJ) by 8.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 120,659 shares of the company’s stock after buying an additional 9,211 shares during the period. Johnson & Johnson makes up about 0.7% of Vinva Investment Management Ltd’s investment portfolio, making the stock its 25th largest holding. Vinva Investment Management Ltd’s holdings in Johnson & Johnson were worth $17,295,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in JNJ. Raymond James Financial Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $1,339,878,000. Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 228.1% in the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock worth $549,223,000 after acquiring an additional 2,356,359 shares during the period. Franklin Resources Inc. grew its position in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after buying an additional 1,729,281 shares during the period. Amundi grew its position in Johnson & Johnson by 16.2% during the fourth quarter. Amundi now owns 11,930,183 shares of the company’s stock valued at $1,698,984,000 after buying an additional 1,660,458 shares during the period. Finally, Holocene Advisors LP bought a new stake in Johnson & Johnson during the third quarter valued at approximately $225,040,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $164.24 on Wednesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company’s fifty day moving average price is $155.73 and its 200-day moving average price is $156.25. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market capitalization of $395.80 billion, a PE ratio of 24.70, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.29 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on JNJ. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Morgan Stanley cut their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Bank of America upped their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.